CGA: Glucose Oxidase, Glucose
What it covers
A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.
The identification in 21 CFR 862.1345, glucose test system. FDA gives CGA no definition of its own, so the regulation’s describes it.
Recent clearances
| 510(k) | Device | Applicant | Decision | Type |
|---|---|---|---|---|
| K252488 | ABL90 FLEX PLUS System | Radiometer Medicals Aps | May 1, 2026 | Traditional |
| K210933 | YSI 2900C Biochemistry Analyzer | Ysi, Inc. | Sep 30, 2024 | Traditional |
| K220328 | EasyStat 300 | Medica Corporation | Jul 26, 2024 | Traditional |
| K223179 | Cholestech LDX System | Alere San Diego, Inc. | Sep 20, 2023 | Dual Track |
| K223755 | i-STAT G cartridge with the i-STAT 1 System | Abbott Point of Care, Inc. | Sep 11, 2023 | Traditional |
| K223710 | i-STAT CG8+ cartridge with the i-STAT 1 System | Abbott Point of Care, Inc. | Jul 28, 2023 | Traditional |
| K223090 | GEM Premier ChemSTAT | Instrumentation Laboratory CO | Jan 27, 2023 | Special |
| K203549 | Nova Primary Glucose Analyzer System | Nova Biomedical Corporation | Oct 18, 2022 | Traditional |
| K210958 | i-STAT CHEM8+ cartridge with the i-STAT 1 System | Abbott Point of Care, Inc. | Aug 13, 2021 | Traditional |
| K200349 | Stat Profile Prime Plus Analyzer System | Nova Biomedical Corporation | Mar 13, 2020 | Traditional |
Clearances by year
52 CGA 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.
| Year | Clearances | Median days to decision |
|---|---|---|
| 2026 (so far) | 1 | 266 |
| 2024 | 2 | 1092 |
| 2023 | 4 | 249 |
| 2022 | 1 | 683 |
| 2021 | 1 | 135 |
| 2020 | 2 | 218 |
| 2019 | 2 | 44 |
| 2018 | 2 | 156 |
| 2017 | 2 | 213 |
| 2016 | 4 | 157 |
| 2015 | 4 | 150 |
| 2014 | 5 | 265 |
| 2013 | 3 | 441 |
| 2012 | 10 | 123 |
| 2011 | 9 | 217 |
Who submits
29 applicants cleared a CGA device since 2011. 65% of the clearances went to applicants in United States, then Taiwan (23%), South Korea (6%) and Denmark (2%). By type: Traditional 69%, Special 29% and Dual Track 2%.
| Applicant | Clearances since 2011 |
|---|---|
| Apex BioTechnology Corp. | 7 |
| Abbott Point of Care, Inc. | 6 |
| Instrumentation Laboratory CO | 4 |
| I-Sens, Inc. | 3 |
| Nova Biomedical Corporation | 3 |
| ACON Laboratories, Inc. | 2 |
| Arkray Factory, Inc. | 2 |
| Bestgen Biotech Corp. | 2 |
How FDA classifies it
Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
From 21 CFR 862.1345. Special controls are the requirements a 510(k) must show it meets.
Standards
21 CFR 862.1345 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent CGA clearances declared.
Ask about CGA
Questions about CGA
What is FDA product code CGA?
Product code CGA, “Glucose Oxidase, Glucose” in FDA's classification database, is a Class II device type under 21 CFR 862.1345 (glucose test system), reviewed by FDA's Clinical Chemistry panel. FDA's 510(k) database lists 401 clearances under CGA, 52 of them since 2011.
How many 510(k) clearances are there under CGA?
FDA’s 510(k) database listed 401 clearances under CGA as of Oct 29, 2026, 52 of them decided since 2011; the most recent decision was May 1, 2026. The Predicate Finder searches the live database.
How long does FDA take to clear a CGA 510(k)?
For the 1 CGA clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 266 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.
Which companies have the most CGA clearances?
Since 2011: Apex BioTechnology Corp. (7), Abbott Point of Care, Inc. (6), Instrumentation Laboratory CO (4), I-Sens, Inc. (3) and Nova Biomedical Corporation (3). 29 applicants have cleared a CGA device in that time.